<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02371525</url>
  </required_header>
  <id_info>
    <org_study_id>5R01MH095628</org_study_id>
    <nct_id>NCT02371525</nct_id>
  </id_info>
  <brief_title>Enhancing PrEP in Community Settings (EPIC)</brief_title>
  <official_title>Enhancing PrEP in Community Settings (EPIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hektoen Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      To test the effectiveness of Prepmate, a novel multi-modal, technology-based intervention for
      pre-exposure prophylaxis (PrEP) adherence support among young men who have sex with men
      (MSM).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PrEP adherence among young MSM over time based on dried blood spot (DBS)</measure>
    <time_frame>DBS measured through week 36</time_frame>
    <description>PrEP adherence during follow-up based on dried blood spot (DBS) concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in PrEP knowledge assessed via computer-assisted self-interview (CASI)</measure>
    <time_frame>baseline and week 36</time_frame>
    <description>Change in PrEP knowledge assessed via computer-assisted self-interview (CASI) at baseline and week 36 (or early termination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in risk behaviors administered via CASI</measure>
    <time_frame>baseline through week 36</time_frame>
    <description>Change in self-reported sexual risk behavior administered via CASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in risk perception administered by CASI</measure>
    <time_frame>baseline through week 36</time_frame>
    <description>Changes in risk perception during the study administered by CASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of Prepmate as measured by an acceptability index collected via CASI</measure>
    <time_frame>Month 9 (or early termination)</time_frame>
    <description>Acceptability of Prepmate as measured by an acceptability index collected via CASI at 9 months (or early termination).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceptions of Prepmate provided via individual exit interviews</measure>
    <time_frame>Month 10</time_frame>
    <description>Qualitative feedback provided via individual exit interviews with a subset of participants one month after Prepmate termination. Interviews will be open-ended and will cover topics such as usability, acceptability, user-experience and effectiveness of the Prepmate intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of use of Prepmate texting service over time as measured by responses to text messages.</measure>
    <time_frame>through week 36</time_frame>
    <description>Use patterns of Prepmate texting service over time as measured by responses to text messages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of sexually-transmitted infection (STI) among all participants.</measure>
    <time_frame>through week 36</time_frame>
    <description>Incidence of a combination endpoint of gonorrhea, chlamydia, and/or syphilis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants who acquire HIV</measure>
    <time_frame>week 36</time_frame>
    <description>The number of HIV infections (2) The drug resistance profiles of breakthrough infections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prepmate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prepmate</intervention_name>
    <description>A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .</description>
    <arm_group_label>Prepmate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-uninfected as determined by a negative/non-reactive laboratory test within 7 days
             of Enrollment (as defined in the study-specific procedures (SSP) Manual).

          -  Interested in initiating PrEP

          -  Eligible to initiate PrEP

               -  Creatinine clearance &gt; 60 ml/min as estimated by the Cockcroft-Gault equation
                  within 6 weeks of enrollment

               -  Hepatitis B surface antigen (HBsAg) negative within 6 weeks Enrollment

               -  No other medical contraindications to PrEP

          -  Age 18 years - 29 years

          -  Willing and able to provide written informed consent

          -  Report having had anal sex with a man in the previous 6 months

          -  Meet any of the following risk criteria for the prior 6 months:

               -  Any condomless anal sex

               -  Three or more anal sex partners

               -  Self-reported new STI

               -  Known HIV-infected sex partner

          -  Have regular access to a computer and/or a smart phone to access the internet and/or
             apps

          -  Have the ability to send and receive text messages

          -  Able to read and speak in English

        Exclusion Criteria:

          -  PrEP use within the past year (PrEP na√Øve participants will be prioritized).

          -  Any reactive or positive HIV test at Screening, even if subsequent testing indicates
             that the person is HIV-uninfected

          -  Prior or current participation in the active arm of an HIV vaccine trial

          -  At Enrollment, has any other condition that, based on the opinion of the investigator
             or designee, would preclude provision of informed consent, make participation in the
             project unsafe, complicate interpretation of outcome data, or otherwise interfere with
             achieving the project objectives.

          -  Signs or symptoms of acute HIV infection (as described in the SSP Manual)

          -  History of pathological bone fracture not related to trauma.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Liu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stroger Hospital and the CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adherence</keyword>
  <keyword>prevention</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

